Table 7 Total projected costs of cervical cancer prevention and control in 2020–2024 (2019 million US dollars)
Programme areas | 2020 | 2021 | 2022 | 2023 | 2024 | Total | Percentage |
|---|---|---|---|---|---|---|---|
Financial | |||||||
Costs of HPV vaccination (including programmatic costs) | 3.2 | 3.4 | 3.6 | 3.9 | 4.2 | 18.3 | 27.1% |
Service delivery costs of screening and pre-cancer treatment | 2.9 | 3.6 | 4.3 | 4.9 | 5.5 | 21.2 | 31.4% |
Service delivery costs of cancer diagnosis, treatment and palliative care | 3.3 | 3.8 | 4.0 | 3.9 | 4.1 | 19.1 | 28.3% |
Programmatic costs of secondary and tertiary prevention | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 9.2 | 13.3% |
Total | 11.2 | 12.6 | 13.7 | 14.5 | 15.6 | 67.6 | 100.0% |
Economic | |||||||
Costs of HPV vaccination (including programmatic costs) | 8.3 | 8.8 | 9.4 | 10. | 10.8 | 47.3 | 38.3% |
Service delivery costs of screening and pre-cancer treatment | 4.3 | 5.4 | 6.3 | 7.0 | 7.8 | 30.8 | 24.9% |
Service delivery costs of cancer diagnosis, treatment and palliative care | 4.5 | 5.1 | 5.3 | 5.2 | 5.4 | 25.5 | 20.6% |
Programmatic costs of secondary and tertiary prevention | 4.0 | 4.0 | 4.0 | 4.0 | 4.0 | 20.0 | 16.2% |
Total | 21.1 | 23.3 | 25.0 | 26.6 | 28.0 | 123.6 | 100% |